Boehringer Ingelheim Press Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Boehringer Ingelheim’s third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 20, 2015 Category: Research Source Type: news

FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment
• BASAGLAR is the first FDA-approved follow-on insulin glargine treatment • BASAGLAR will be available in the U.S. starting on December 15, 2016 (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 15, 2015 Category: Research Source Type: news

First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
• New study explores safety and tolerability of OFEV plus pirfenidone, versus OFEV alone • First multinational study involving 100 patients to investigate a combination of two approved drugs   for idiopathic pulmonary fibrosis (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 13, 2015 Category: Research Source Type: news

New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched
• First person enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS)   study investigating nintedanib in people with systemic sclerosis who also develop interstitial lung   disease (SSc-ILD) • Phase III trial is now open for recruitment • After demonstrating that nintedanib slows disease progression in idiopathic pulmonary fibrosis,   Boehringer Ingelheim is expanding its research with nintedanib into other serious fibrotic lung   conditions that arise in association with rare diseases like systemic sclerosis (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 7, 2015 Category: Research Source Type: news

Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
● Pancreatic ductal adenocarcinoma is one of the most lethal of cancers with no effective treatments    available ● Boehringer Ingelheim and MD Anderson Cancer Center to identify new therapeutic concepts,    biomarkers and develop breakthrough medicines to treat pancreatic cancer ● This collaboration underscores Boehringer Ingelheim’s focus on difficult-to-treat diseases and    commitment to precision medicines (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 1, 2015 Category: Research Source Type: news